Therapy Areas: Inflammatory Diseases
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
24 July 2024 - California-based biotechnology company Anixa Biosciences Inc (NASDAQ: ANIX) announced on Tuesday that the US Food and Drug Administration (FDA) has granted approval to the company'...
Biotheryx doses first patient in BTX-9341 phase one clinical trial as a monotherapy and in combination with fulvestrant for HR+/HER2- Breast Cancer
18 July 2024 - Biotheryx, Inc., a California-based biopharmaceutical company discovering and developing a portfolio of protein degraders with a focus on validated targets in cancer and inflammatory di...
SFA Therapeutics names new chief operating officer
17 July 2024 - US clinical-stage biopharmaceutical company SFA Therapeutics Inc announced on Tuesday the appointment of James Kirwin, MBA, as its new chief operating officer.In this role, Kirwin will ...
argenx and Zai Lab win China approval for efgartigimod SC
16 July 2024 - Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) and biopharmaceutical company Zai Lab Limited (Nasdaq:ZLAB) (HKEX:9688) revealed on Tuesday that they have received C...
Scinai Immunotherapeutics reports positive results in psoriasis study
15 July 2024 - Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical firm that specialises in inflammation and immunology (I&I) biological products, on Monday announced successful in-v...
Johnson & Johnson acquires Yellow Jersey Therapeutics
11 July 2024 - Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) confirmed on Thursday that it has completed the acquisition of Yellow Jersey Therapeutics for USD1.25bn.Through th...